Form 4: Arcutis Biotherapeutics Director Increases Stake with Recent Stock Purchases

Patrick J. Heron, a Director at Arcutis Biotherapeutics, Inc., has increased his beneficial ownership in the company through recent stock purchases totaling 2,268 shares.

Summary

• Patrick J. Heron, a Director of Arcutis Biotherapeutics, Inc. (ARQT), reported two separate purchases of common stock.
• On June 4, 2025, Mr. Heron indirectly acquired 1,890 shares of common stock at a weighted average price of $13.3214 per share through Frazier Life Sciences X, L.P.
• On June 5, 2025, an additional 378 shares were indirectly acquired at a weighted average price of $13.4108 per share, also through Frazier Life Sciences X, L.P.
• These transactions bring the total shares beneficially owned by Mr. Heron, directly and indirectly, to 8,852,627 shares.
• The indirect holdings include 24,802 shares via Frazier Life Sciences X, L.P., 8,785,284 shares via Frazier Life Sciences VIII, L.P., 7 shares via FHM Life Sciences VIII, L.L.C., and 23,688 shares via The Heron Living Trust 11/30/2004, in addition to 18,826 shares held directly.

Sentiment

Score: 7

Explanation: The sentiment is positive due to a director's open market purchases, indicating confidence in the company's stock. However, a Form 4 alone does not provide comprehensive financial or operational details to warrant a higher score.

Positives

• A director increasing their stake in the company through open market purchases signals confidence in the company's future prospects and valuation.
• The purchases were made at prices ranging from $13.26 to $13.50, indicating a belief in the stock's value at these levels.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider buying, such as reported in this Form 4, is often interpreted by the market as a positive signal, suggesting that those with intimate knowledge of the company believe its stock is undervalued or that positive developments are anticipated. This can be particularly impactful in the biotechnology sector where future success is often tied to clinical trial outcomes and regulatory approvals.

Related Party Transactions

• The majority of the shares are held indirectly through Frazier Life Sciences X, L.P., Frazier Life Sciences VIII, L.P., and FHM Life Sciences VIII, L.L.C., where the Reporting Person is a managing member. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.
• Shares are also held indirectly through The Heron Living Trust 11/30/2004, where the Reporting Person is a co-trustee with voting and investment power.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive indicator of future stock performance and management's belief in the company's value.

Key Dates

Recommendation

Keywords

Arcutis Biotherapeutics, ARQT, Form 4, Insider Trading, Stock Purchase, Director, Beneficial Ownership, Frazier Life Sciences